Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): ATYR2810

            Therapeutic Area: Oncology Product Name: ATYR2810

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: aTyr Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership April 14, 2021

            Details:

            Under the terms of the agreement, Lonza will utilize its Ibex® Design, a fully integrated end-to-end program, to manufacture cGMP material for ATYR2810.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): TAC01-HER2

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Triumvira Immunologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 24, 2020

            Details:

            Collaboration, aimed at developing Triumvira’s TAC01-HER2 T-cell therapy for solid tumors, will leverage Lonza’s expertise in process development and the usage of its proprietary Cocoon® Platform.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BITR2101

            Therapeutic Area: Oncology Product Name: BITR2101

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: BITT

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 09, 2021

            Details:

            The agreement focuses to develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 (TNFR2) antagonist antibody for the treatment of cancers and infectious diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IL-2 conjugates

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ridgeline Therapeutics Discovery

            Deal Size: $35.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 28, 2020

            Details:

            Bright Peak’s technology platform allows a wide range of proteins to be chemically assembled de novo. The company has validated the platform by creating a portfolio of designer cytokines with the potential to be advanced as novel immune-oncology therapeutics.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ND021

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: 3SBio

            Deal Size: $23.8 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing March 09, 2020

            Details:

            With the financing secured, Numab plans to further broaden its proprietary pipeline and accelerate the development for a number of programs towards the clinic.